U.S. Markets closed

Allergan plc (AGN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
223.99-0.78 (-0.35%)
At close: 4:02PM EDT
People also watch
BIIBCELGVRXGILDREGN
  • u
    unimpressedinweston
    unimpressedinweston
    Does anyone find this comment remarkably familiar?

    "$AGN ...lmao...I told you sheep 2 months ago this was going to $180...it was $260 then...$224 now....and dropping every day!! saunders..lol"

    This is from CNN with the name Sonofsam Aug. 17 at 1:42 PM. Tuna, Thurston, Sonofsam are all irritants. Glad my mute works. John is next.
  • F
    Finkelstein
    Finkelstein

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • G
    GeraldF
    GeraldF
    oversold territory. buy.
  • J
    Jasmine
    Jasmine
    AGN has just seen the last of the selling. Looks like a potential push higher is in store. google awesom_sto-cks - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • g
    garroty
    garroty
    Apparently this company was standing on cricket legs. They're running to the exits!
  • G
    GeraldF
    GeraldF
    oversold
    buy.
  • J
    John
    John
    Is it too late to short? It can't keep dropping every day.
  • T
    Thurston
    Thurston
    AGN can't eve pump its own stock no matter how hard they try the market dies. It trust this management!!! All news is bad news when dealing with an irresponsible ego maniac!!! God blesss colonel saunders
  • G
    GeraldF
    GeraldF
    oversold. time to add.
  • G
    GeraldF
    GeraldF
    time to buy. way oversold.
  • g
    garroty
    garroty
    I think we all owe Thurston an apology. He was right. If we had shorted at $250 we'd be drinking Mai Tai's on the beach in Maui today. This thing's way too fat. I asked him at $235 if we'd hit the floor- he said we hadn't . He was right again. I'm gonna go out on a limb and say we're headed to $200 by Sept. 1. This hogs being butchered by some big funds.
  • T
    Thurston
    Thurston
    Remember when the dumb geese like jie were predicting 500 590 even 1000 per share and the stock dropped 50% yes nearly 59% in s straight line 347 to 184.5 I was bearish and the geese pumped the whole way down !!! No the diwnside is even worse since AGN is failing and has hidden losses
  • T
    Thurston
    Thurston
    AGN is a pig which is loaded with fat. AGN just started cutting the fat and laying off sales reps since they don't sell anything but boyox
  • J
    John
    John
    Until they announce the sale of their TEVA shares, this will continue to drop. I cannot believe the CEO was foolish enough to hold on to them.
  • T
    Thurston
    Thurston
    Cannot trade on Saturday? If it would it would be 17 out of 18 will we have to wait until Monday for the waterfall
  • T
    Thurston
    Thurston
    Geese you gonna lose everything !!! Something is gone wrong at this mud hole.
  • T
    Thurston
    Thurston
    Geese there is no PE fir AGN!! The market understand the financial manipulation that AGN does with it non gaap earnings which are not real!!! The market is saying AGN is in serious trouble and to sell everythinh
  • T
    Thurston
    Thurston
    AGN market. So must come down to a more reasonable 25 billion
  • T
    Thurston
    Thurston
    No news is bad news as the selling will continue unabated good news will not happen as AGN management has no market. Incidence anybinkling of bad news and AGN goes straight to 170
  • a
    all ready know
    all ready know
    Trade Tip...News is leaking for positive Phase 3 data to be released by Monday. Stock price is beginning to rise on the leak. Cancer/Leukemia drug will spike big time upon press release.

    VSTM
    $3.16
    +0.01 (+0.31%) Duvelisib - DUO
    Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
    Phase 3

    08/31/2017
    Phase 3 data due late summer 2017.